Testing epcoritamab plus ibrutinib for lymphoma in the brain and spinal cord
Original title: A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people, meant to check safety first.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing whether two drugs given together are safe for people with lymphoma in the central nervous system.
Who this trial is for. This trial is for people with primary or secondary central nervous system lymphoma that has come back or did not respond to earlier treatment. It tests two drugs given together, epcoritamab and ibrutinib.
Where it stands. The trial is looking at whether this drug pair is safe and whether it causes few or mild side effects. The answer is not in yet. The trial has not reported results.
What this means, and what it doesn't
What it could mean: If your lymphoma has come back or did not respond to treatment, this is one option being studied. You could ask your care team whether a trial like this fits your situation. They can explain what taking part would involve.
What it doesn't mean: This does not mean the drug pair works. A trial is a test, not a proven treatment. Joining a trial is not a guarantee that it will help you. It is not a promise of a cure. Only the trial team can decide who can take part.
Source: ClinicalTrials.gov, July 14, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.